Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S11-20. Unique Identifier : AIDSLINE MED/95169465
Mestecky J; Kutteh WH; Jackson S; Department of Microbiology and Medicine, University of Alabama at; Birmingham.

Abstract: The development of vaccines that induce specific immune responses in the genital tract secretions would have far-reaching implications for the prevention of AIDS and other sexually transmitted diseases. Most of the currently studied vaccines utilize systemic routes of immunization that are of limited value for the prevention of mucosa-contracted diseases. The relative contribution of antigen-sensitized cells and IgA-committed lymphocytes from IgA inductive sites (e.g., Peyer's patches and rectal tonsils) to remote or adjacent effector sites (e.g., salivary glands and female genital tract) as manifested by the appearance of corresponding secretory antibodies has not been studied in humans despite its unquestionable practical importance. Exploitation of immunization routes that are effective for induction of mucosal immune responses and reflect our current knowledge of the origin of antibodies and of specific antibody-forming cells in mucosal tissues is likely to reduce the incidence of many infectious diseases including AIDS.
Keywords: Animal Antibody-Producing Cells/IMMUNOLOGY AIDS Vaccines/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Female Genitalia, Female/*IMMUNOLOGY Human HIV Infections/*PREVENTION & CONTROL IgA/METABOLISM Immunoglobulins/METABOLISM Mucous Membrane/IMMUNOLOGY Support, U.S. Gov't, P.H.S. Vaccination/METHODS JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDanimalantibody-producingcells/immunologyaidsvaccines/administration&dosage/KWDpharmacologyfemalegenitalia,female/KWDimmunologyhumanhivinfections/KWDprevention&controliga/metabolismimmunoglobulins/metabolismmucousmembrane/immunologysupport,uKWDsKWDgov't,pKWDhKWDsKWDvaccination/methodsjournalarticlereviewreview,tutorial
950630
M9561151

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .